FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
VYNE Therapeutics FCF Yield % Related Terms
VYNE Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for VYNE Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VYNE Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VYNE Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where VYNE Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics (VYNE) has a FCF Yield % of -118.50 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on VYNE Therapeutics and its competitors. According to the industry distribution chart, VYNE Therapeutics ranks #1303 out of 1415 companies in the Biotechnology industry, placing it in the top 92.1%.
Is VYNE Therapeutics' FCF Yield % too high?
VYNE Therapeutics' current FCF Yield % is -118.50. Based on the distribution chart, VYNE Therapeutics ranks #1303 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VYNE Therapeutics has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does VYNE Therapeutics' FCF Yield % compare to PLUR and MRKR?
According to the Biotechnology industry distribution chart, VYNE Therapeutics ranks #1303 out of 1415 companies for FCF Yield %. This places VYNE Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on VYNE Therapeutics and its competitors. VYNE Therapeutics's current FCF Yield % is -118.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VYNE Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, VYNE Therapeutics (VYNE) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.55, compared to a current price of $0.65 — trading 18.6% above its estimated fair value. The current FCF Yield % is -118.50. VYNE Therapeutics' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For VYNE Therapeutics (VYNE), the current FCF Yield % is -118.50 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VYNE Therapeutics (VYNE) Overvalued in 2026?
Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be overvalued.
The current stock price of $0.65 is trading 18.6% above its estimated GF Value™ of $0.55.
GuruFocus considers VYNE Therapeutics to be Modestly Overvalued.
Key valuation signals for VYNE:
FCF Yield %: -118.50
GF Value™: $0.55 vs. price of $0.65 (18.6% above fair value)
No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
37GF Score
Get the complete analysis for VYNE
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYNE has been successfully added to your 
